Dosing and administration
The recommended dose of SPEVIGO® is a single continuous IV infusion of 900 mg administered over 90 minutes1
If flare symptoms persist, an additional IV infusion may be administered 1 week after the initial dose.1
*Pustular clearance defined as GPPGA pustulation subscore of 0 (no visible pustules).1
†Flare control defined as GPPGA total score ≤1 and was reported for the 12-week study.1,3
‡Flare persistence defined as GPPGA total score ≥2 and GPPGA pustulation subscore ≥2.3
GPP=Generalized Pustular Psoriasis; GPPGA=Generalized Pustular Psoriasis Physician Global Assessment; IV=intravenous.
One dose is all you may need to Control the danger of GPP flares like never before1-3
The recommended dose of SPEVIGO® is a single continuous IV infusion of 900 mg administered over 90 minutes1
*Pustular clearance defined as GPPGA pustulation subscore of 0 (no visible pustules).1
†Flare control defined as GPPGA score of 0-1 and was reported for the 12-week study.3
‡Flare persistence defined as GPPGA total score of 2 or more and GPPGA pustulation subscore of 2 or more.3
GPP=Generalized Pustular Psoriasis; GPPGA=Generalized Pustular Psoriasis; Physician Global Assessment; IV=intravenous.
References
-
SPEVIGO® Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals, Inc; 2022.
-
Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666. doi:10.1136/bmjopen-2020-043666
-
Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563